home / stock / ngenf / ngenf news

NGENF News and Press, NervGen Pharma Corp From 01/10/22

Stock Information
Company Name: NervGen Pharma Corp
Stock Symbol: NGENF
Market: OTC
Website: nervgen.com
Menu
NGENF NGENF Quote NGENF Short NGENF News NGENF Articles NGENF Message Board
Get NGENF Alerts

News, Short Squeeze, Breakout and More Instantly...
NGENF - NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation

Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury “The ability of NVG-291 to demonstrate meaningful recovery in motor function, sen...
NGENF - NervGen Pharma Applauds President Biden Signing Defense Bill

Department of Defense now able to Move Forward on Brain Plasticity Research Cincinnati, Ohio--(Newsfile Corp. - January 4, 2022) - NervGen Pharma Corp.,  (TSXV: NGEN) (OTCQX: NGENF )  through its subsidiary, NervGen US Inc., ("NervGen" or the "Company"), a clinical stage biotech ...

NGENF - NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial

Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen's NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer's disease indications Screening of healthy volunteers has already started for the trial's multiple ascending dose (MAD) portion In preclinical stu...

NGENF - NervGen Pharma Reports Third Quarter 2021 Results

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its fina...
NGENF - NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021

Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the Trial Vancouver, British Columbia--(Newsfile Corp. - November 4, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF ) ("NervGen" or the "Company"), a clinical stage biotech company dedi...

NGENF - NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spina...

NGENF - NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting

NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile Vancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF ) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating ...
NGENF - U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury

Cincinnati, Ohio--(Newsfile Corp. - October 4, 2021) - NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSXV: NGEN) (OTCQX: NGENF ) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the...

NGENF - NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a par...

NGENF - Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.

Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF). The full research publication can be found on our website at www.encodelp.com , or by clicking here . Encode Ideas, L.P., a healthcare focused ...
Previous 10 Next 10